This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sommerfeld, H.-J. Articles by Coffey, D. S. Search for Related Content PubMed PubMed Citation Articles by Sommerfeld, H.-J. Articles by Coffey, D. S.

Telomerase Activity: A Prevalent Marker of Malignant Human Prostate Tissue¹

Kath. Marienhospital II, Urologische Klinik, Ruhr Universitat Bochum, Widumer Strasse 8, 44627 Herne, Germany [H-J. S.]; James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287 [A. K. M., G. S. B., D. S. C.]; and University of Texas Southwestern Medical Center at Dallas, Department of Cell Biology and Neurosciences, Dallas, Texas 75235 [M. A. P., J. W. S.]

We urgently need biochemical markers to detect the malignant nature and pathological states of the human prostate. We report that telomerase activity is associated with prostate cancer but absent in the benign disease and normal gland. Telomerase is, therefore, a potential diagnostic marker for prostate cancer.

Twenty-five human prostates resected at the time of radical prostatectomy were dissected to obtain matched adjacent areas of normal, central zone benign prostatic hyperplasia (BPH), and pathologically confirmed cancer tissue. These matched tissue samples were assayed for telomerase activity using a sensitive PCR technique. None of the normal tissues exhibited telomerase activity. In contrast, 21 of the 25 (84%) cancers were strongly positive. At the time of prostatectomy, four lymph nodes were positive for metastases and all were strongly positive for telomerase activity. In adjacent BPH tissues taken from the cancerous prostates, only 3 of the 25 tissues (12%) were weakly positive. Telomerase activity was not detected in ten BPH samples recovered from patients who underwent open surgery solely for BPH. All five available cell lines of human prostate cancer (DU145, LNCaP, PC3, PPC1, and TSU) were strongly positive.

Short telomere lengths have been observed in several human cancers. We also measured the telomere lengths in 27 matched samples of normal, BPH, and cancer tissue taken from nine radical prostatectomies. The telomeres from cancer tissue were significantly and consistently shorter than either the adjacent normal or adjacent BPH tissues.

Our results indicate that telomerase activity, as well as telomere lengths, may be markers for distinguishing prostate cancer from normal and benign prostate tissues.

¹ Supported by SPORE Grants CA 58236, DK 2200, DK 19300, and CA 15416.

² To whom requests for reprints should be addressed, at James Buchanan Brady Urological Institute, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287; Phone: (410) 955-2519; Fax: (410) 955-0833.

Received 8/ 7/95. Accepted 10/31/95.

This article has been cited by other articles:

				M. A. Shammas, A. Qazi, R. B. Batchu, R. C. Bertheau, J. Y.Y. Wong, M. Y. Rao, M. Prasad, D. Chanda, S. Ponnazhagan, K. C. Anderson, et al. Telomere Maintenance in Laser Capture Microdissection-Purified Barrett's Adenocarcinoma Cells and Effect of Telomerase Inhibition In vivo Clin. Cancer Res., August 1, 2008; 14(15): 4971 - 4980. [Abstract] [Full Text] [PDF]

				U. Moehren, M. Papaioannou, C. A. Reeb, A. Grasselli, S. Nanni, M. Asim, D. Roell, I. Prade, A. Farsetti, and A. Baniahmad Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development FASEB J, April 1, 2008; 22(4): 1258 - 1267. [Abstract] [Full Text] [PDF]

				J. Shen, M. B. Terry, I. Gurvich, Y. Liao, R. T. Senie, and R. M. Santella Short Telomere Length and Breast Cancer Risk: A Study in Sister Sets Cancer Res., June 1, 2007; 67(11): 5538 - 5544. [Abstract] [Full Text] [PDF]

				J. Miki, B. Furusato, H. Li, Y. Gu, H. Takahashi, S. Egawa, I. A. Sesterhenn, D. G. McLeod, S. Srivastava, and J. S. Rhim Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT-Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens Cancer Res., April 1, 2007; 67(7): 3153 - 3161. [Abstract] [Full Text] [PDF]

				S. Nanni, C. Priolo, A. Grasselli, M. D'Eletto, R. Merola, F. Moretti, M. Gallucci, P. De Carli, S. Sentinelli, A. M. Cianciulli, et al. Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer Mol. Cancer Res., February 1, 2006; 4(2): 79 - 92. [Abstract] [Full Text] [PDF]

				C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF]

				G. I. Botchkina, R. H. Kim, I. L. Botchkina, A. Kirshenbaum, Z. Frischer, and H. L. Adler Noninvasive Detection of Prostate Cancer by Quantitative Analysis of Telomerase Activity Clin. Cancer Res., May 1, 2005; 11(9): 3243 - 3249. [Abstract] [Full Text] [PDF]

				V. Kundra, J. F. Krane, P. Nikolaidis, D. S. Green, K. H. Zou, K. Tuncali, E. vanSonnenberg, and S. G. Silverman Telomerase Activity Predicts Malignancy in Percutaneous Image-guided Needle Biopsy Specimens of the Abdomen and Pelvis Radiology, March 1, 2005; 234(3): 941 - 947. [Abstract] [Full Text] [PDF]

				D.A. LAWSON, L. XIN, R. LUKACS, Q. XU, D. CHENG, and O.N. WITTE Prostate Stem Cells and Prostate Cancer Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 187 - 196. [Abstract] [PDF]

				A. Biroccio and C. Leonetti Telomerase as a new target for the treatment of hormone-refractory prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 407 - 421. [Abstract] [Full Text] [PDF]

				T. Ozawa, S. M. Gryaznov, L. J. Hu, K. Pongracz, R. A. Santos, A. W. Bollen, K. R. Lamborn, and D. F. Deen Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts Neuro-oncol, July 1, 2004; 6(3): 218 - 226. [Abstract] [PDF]

				A. Ohali, S. Avigad, I.J. Cohen, I. Meller, Y. Kollender, J. Issakov, I. Gelernter, Y. Goshen, I. Yaniv, and R. Zaizov Association Between Telomerase Activity and Outcome in Patients With Nonmetastatic Ewing Family of Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3836 - 3843. [Abstract] [Full Text] [PDF]

				R. Schroers, L. Shen, L. Rollins, C. M. Rooney, K. Slawin, G. Sonderstrup, X. F. Huang, and S.-Y. Chen Human Telomerase Reverse Transcriptase-Specific T-Helper Responses Induced by Promiscuous Major Histocompatibility Complex Class II-Restricted Epitopes Clin. Cancer Res., October 15, 2003; 9(13): 4743 - 4755. [Abstract] [Full Text] [PDF]

				S K Mohanty and P Dey Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review Postgrad. Med. J., October 1, 2003; 79(936): 569 - 574. [Abstract] [Full Text] [PDF]

				M. A. Shammas, R. J. Shmookler Reis, M. Akiyama, H. Koley, D. Chauhan, T. Hideshima, R. K. Goyal, L. H. Hurley, K. C. Anderson, and N. C. Munshi Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma Mol. Cancer Ther., September 1, 2003; 2(9): 825 - 833. [Abstract] [Full Text] [PDF]

				M. F. Leitzmann, M. J. Stampfer, K. Wu, G. A. Colditz, W. C. Willett, and E. L. Giovannucci Zinc Supplement Use and Risk of Prostate Cancer J Natl Cancer Inst, July 2, 2003; 95(13): 1004 - 1007. [Abstract] [Full Text] [PDF]

				K. A. Iczkowski and C. G. Pantazis Overexpression of NSAID-Activated Gene Product in Prostate Cancer International Journal of Surgical Pathology, July 1, 2003; 11(3): 159 - 166. [Abstract] [PDF]

				M. A. Khan and A. W. Partin Management of High-Risk Populations with Locally Advanced Prostate Cancer Oncologist, June 1, 2003; 8(3): 259 - 269. [Abstract] [Full Text] [PDF]

				A. K. Meeker, J. L. Hicks, E. A. Platz, G. E. March, C. J. Bennett, M. J. Delannoy, and A. M. De Marzo Telomere Shortening Is an Early Somatic DNA Alteration in Human Prostate Tumorigenesis Cancer Res., November 15, 2002; 62(22): 6405 - 6409. [Abstract] [Full Text] [PDF]

				S.-Q. Xu, M. He, H.-P. Yu, X.-Y. Wang, X.-L. Tan, B. Lu, X. Sun, Y.-K. Zhou, Q.-F. Yao, Y.-J. Xu, et al. Bioluminescent Method for Detecting Telomerase Activity Clin. Chem., July 1, 2002; 48(7): 1016 - 1020. [Abstract] [Full Text] [PDF]

				R. Schroers, X. F. Huang, J. Hammer, J. Zhang, and S.-Y. Chen Identification of HLA DR7-restricted Epitopes from Human Telomerase Reverse Transcriptase Recognized by CD4+ T-Helper Cells Cancer Res., May 1, 2002; 62(9): 2600 - 2605. [Abstract] [Full Text] [PDF]

				J. B. de Kok, G. W. Verhaegh, R. W. Roelofs, D. Hessels, L. A. Kiemeney, T. W. Aalders, D. W. Swinkels, and J. A. Schalken DD3PCA3, a Very Sensitive and Specific Marker to Detect Prostate Tumors Cancer Res., May 1, 2002; 62(9): 2695 - 2698. [Abstract] [Full Text] [PDF]

				A. K. Meeker, W. R. Gage, J. L. Hicks, I. Simon, J. R. Coffman, E. A. Platz, G. E. March, and A. M. De Marzo Telomere Length Assessment in Human Archival Tissues : Combined Telomere Fluorescence in Situ Hybridization and Immunostaining Am. J. Pathol., April 1, 2002; 160(4): 1259 - 1268. [Abstract] [Full Text] [PDF]

				Y. Yasunaga, K. Nakamura, C. M. Ewing, W. B. Isaacs, B. Hukku, and J. S. Rhim A Novel Human Cell Culture Model for the Study of Familial Prostate Cancer Cancer Res., August 1, 2001; 61(16): 5969 - 5973. [Abstract] [Full Text] [PDF]

				J. W. Shay, Y. Zou, E. Hiyama, and W. E. Wright Telomerase and cancer Hum. Mol. Genet., April 1, 2001; 10(7): 677 - 685. [Abstract] [Full Text] [PDF]

				K. Aogi, A. Woodman, V. Urquidi, D. C. Mangham, D. Tarin, and S. Goodison Telomerase Activity in Soft-Tissue and Bone Sarcomas Clin. Cancer Res., December 1, 2000; 6(12): 4776 - 4781. [Abstract] [Full Text]

				C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]

				C. Sandhu, D. M. Peehl, and J. Slingerland p16INK4A Mediates Cyclin Dependent Kinase 4 and 6 Inhibition in Senescent Prostatic Epithelial Cells Cancer Res., May 1, 2000; 60(10): 2616 - 2622. [Abstract] [Full Text]

				T. Gunther, R. Schneider-Stock, C. Hackel, M. Pross, H.-U. Schulz, H. Lippert, and A. Roessner Telomerase Activity and Expression of hTRT and hTR in Gastrointestinal Stromal Tumors in Comparison with Extragastrointestinal Sarcomas Clin. Cancer Res., May 1, 2000; 6(5): 1811 - 1818. [Abstract] [Full Text] [PDF]

				K. Aogi, K. Kitahara, V. Urquidi, D. Tarin, and S. Goodison Comparison of Telomerase and CD44 Expression as Diagnostic Tumor Markers in Lesions of the Thyroid Clin. Cancer Res., October 1, 1999; 5(10): 2790 - 2797. [Abstract] [Full Text] [PDF]

				S. Sigala, I. Faraoni, D. Botticini, M. Paez-Pereda, C. Missale, E. Bonmassar, and P. Spano Suppression of Telomerase, Reexpression of KAI1, and Abrogation of Tumorigenicity by Nerve Growth Factor in Prostate Cancer Cell Lines Clin. Cancer Res., May 1, 1999; 5(5): 1211 - 1218. [Abstract] [Full Text] [PDF]

				E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]

				T. Yajima, A. Yagihashi, H. Kameshima, D. Kobayashi, D. Furuya, K. Hirata, and N. Watanabe Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system Clin. Chem., December 1, 1998; 44(12): 2441 - 2445. [Abstract] [Full Text] [PDF]

				M. Hirose, J. Abe-Hashimoto, H. Tahara, T. Ide, and T. Yoshimura New method to measure telomerase activity by transcription-mediated amplification and hybridization protection assay Clin. Chem., December 1, 1998; 44(12): 2446 - 2452. [Abstract] [Full Text] [PDF]

				J. Yui, C.-P. Chiu, and P. M. Lansdorp Telomerase Activity in Candidate Stem Cells From Fetal Liver and Adult Bone Marrow Blood, May 1, 1998; 91(9): 3255 - 3262. [Abstract] [Full Text] [PDF]

				P. P. Banerjee, S. Banerjee, B. R. Zirkin, and T. R. Brown Lobe-Specific Telomerase Activity in the Intact Adult Brown Norway Rat Prostate and Its Regional Distribution within the Prostatic Ducts Endocrinology, February 1, 1998; 139(2): 513 - 519. [Abstract] [Full Text] [PDF]

				C. W. Greider Telomerase activity, cell proliferation, and cancer PNAS, January 6, 1998; 95(1): 90 - 92. [Full Text] [PDF]

				C. D. Belair, T. R. Yeager, P. M. Lopez, and C. A. Reznikoff Telomerase activity: A biomarker of cell proliferation, not malignant transformation PNAS, December 9, 1997; 94(25): 13677 - 13682. [Abstract] [Full Text] [PDF]

				R. Dahse, W. Fiedler, and G. Ernst Telomeres and telomerase: biological and clinical importance Clin. Chem., May 1, 1997; 43(5): 708 - 714. [Abstract] [Full Text] [PDF]

				B. Minev, J. Hipp, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti Cytotoxic T cell immunity against telomerase reverse transcriptase in humans PNAS, April 25, 2000; 97(9): 4796 - 4801. [Abstract] [Full Text] [PDF]